Defunct Company
Total Trials
28
As Lead Sponsor
6
As Collaborator
22
Total Enrollment
1,195
NCT00650572
A Study of ARRY-380 in Patients With Advanced HER2+ Cancer
Phase: Phase 1
Role: Collaborator
Start: May 31, 2008
Completion: Mar 31, 2013
NCT00859755
A Safety Study of ARRY-403 in Patients With Type 2 Diabetes
Role: Lead Sponsor
Start: Mar 31, 2009
Completion: Not specified
NCT00862524
A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer
Phase: Phase 1/2
Completion: Feb 28, 2011
NCT01449058
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Start: Mar 31, 2012
Completion: Aug 15, 2017
NCT01828034
First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma
Start: Apr 30, 2013
Completion: May 30, 2019
NCT01777776
Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.
Start: Jul 31, 2013
Completion: Apr 30, 2015
NCT01894672
BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation
Phase: Phase 2
Completion: Mar 17, 2016
NCT01921335
ARRY-380 + Trastuzuamab for Breast w/ Brain Mets
Start: Aug 31, 2013
Completion: Dec 31, 2023
NCT01820364
LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma
Start: Nov 30, 2013
Completion: Mar 31, 2015
NCT01859026
A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation
Start: Dec 30, 2013
Completion: Aug 22, 2019
NCT02041481
MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer
Start: Jun 30, 2014
Completion: Jan 19, 2018
NCT02089230
MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy
Start: Aug 27, 2014
Completion: Jun 5, 2019
NCT02510001
MEK and MET Inhibition in Colorectal Cancer
Start: Nov 30, 2014
Completion: Dec 3, 2018
NCT02278133
Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations
Start: Dec 31, 2014
Completion: Jun 23, 2017
NCT02225574
An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)
Start: Mar 11, 2015
Completion: Feb 2, 2017
NCT02384083
Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients
Start: Sep 30, 2015
Completion: Mar 23, 2020
NCT02834364
BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)
Start: Jun 30, 2016
Completion: Mar 29, 2023
NCT03158103
A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
Start: Apr 15, 2017
Completion: Apr 28, 2021
NCT03170206
Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer
Start: May 31, 2017
Completion: Dec 31, 2025
NCT03231306
Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas
Start: Nov 28, 2017
Completion: Apr 17, 2024
NCT03374254
Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651)
Start: Feb 16, 2018
Completion: Jul 18, 2023
NCT03843775
A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers
Start: Feb 14, 2019
Completion: Sep 2, 2023
NCT03971409
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
Start: Jul 8, 2019
Completion: Jun 30, 2026
NCT04005144
Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer
Start: Feb 25, 2020
Completion: Oct 1, 2022
NCT04292119
Lorlatinib Combinations in Lung Cancer
Start: May 1, 2020
Completion: Mar 1, 2023
NCT04074967
Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab
Start: Jun 11, 2020
Completion: Oct 1, 2025
NCT04375527
Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma
Start: Dec 3, 2020
Completion: Nov 22, 2024
NCT04598009
Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
Start: Mar 3, 2021
Completion: May 31, 2027